Adult ADHD Treatment in New Jersey

Adult ADHD treatment is not one thing. It usually combines medication when it fits, practical changes at work and home, and sometimes therapy or coaching, adjusted over months. In New Jersey, how that treatment is delivered also depends on state rules that changed twice in 2026. This page covers what the evidence supports for adults, what New Jersey law adds, and where Dr. Shershow's care fits.

What evidence-based adult ADHD treatment includes

NIMH says the two most common treatments for adult ADHD are medication and psychotherapy, and that effective treatment often combines elements. Two widely used clinical summaries go further:

A large 2018 network meta-analysis in Lancet Psychiatry (Cortese and colleagues) weighed both effectiveness and safety and supported amphetamines as a preferred first choice in adults for short-term treatment, while calling for more research on long-term effects. Individual response varies. NIMH notes that people sometimes try several treatments before finding the one that works.

As of October 19, 2026, APSARD's first US guideline for adult ADHD was in final review and not yet published. Until it is, clinicians rely on sources like the ones above. The full picture is in clinical guidelines for adult ADHD.

Where Dr. Shershow's care fits

Dr. Shershow provides the medical side of treatment: an evaluation that ends with what it found and the treatment options that fit, a treatment plan, medication management when medication is appropriate, and ongoing psychiatric follow-up, with follow-up visits by secure video. If therapy, coaching or testing would help, Dr. Shershow can include it in the plan, but the practice does not provide those services. More on the approach is on the adult ADHD treatment page.

What New Jersey law adds to treatment

Treatment with a stimulant in New Jersey runs on a calendar set by law. Under P.L.2026, c.40, approved July 8, 2026, for an adult located in New Jersey:

The Division of Consumer Affairs repeated these rules in a notice dated August 3, 2026. Earlier in 2026 the rules were stricter: after the COVID-era waivers ended on February 16, 2026, the Division told prescribers that no new patient could receive a Schedule II prescription before an in-person visit. Information written before July 2026 may describe that period. The office will explain how visits are arranged for patients located in New Jersey. The detail is in telehealth ADHD prescriptions in New Jersey in 2026.

Other New Jersey rules shape the prescription itself. The Board of Medical Examiners' rule, N.J.A.C. 13:35-7.6, requires a physician starting a controlled substance to take a thorough history, do an appropriate examination that includes coexisting conditions such as anxiety and depression, check the state Prescription Monitoring Program, and write a treatment plan. A single Schedule II prescription is limited to a 30-day supply, though a physician may issue multiple prescriptions covering up to 90 days with earliest fill dates. How this works month to month is on the ADHD medication management in New Jersey page.

If you split your week between New Jersey and New York

Many New Jersey adults work in Manhattan. The rules that apply to a visit follow where you are physically located at the time, not your home address. New Jersey's telehealth law requires a New Jersey license for services provided in New Jersey, and Dr. Shershow is licensed in both states. Federal DEA telemedicine flexibilities for controlled substances run through December 31, 2026, and what replaces them in 2027 had not been published as of October 2026. Tell the office where you will usually be for visits and keep it consistent. The cross-border details are in living in New Jersey, getting ADHD care in New York.

Monitoring: what follow-up is for

Follow-up is where treatment gets adjusted. NICE recommends monitoring how well medication works and its side effects, checking heart rate and blood pressure before and after each dose change and every six months, and checking weight every six months in adults. The FDA updated the boxed warning on all prescription stimulants in 2023 to describe the risks of misuse, abuse, addiction and overdose, and advises prescribers to assess that risk before prescribing and to monitor for it during treatment. These are reasons follow-up is a standing part of care, not a formality. See ADHD follow-up visits in New Jersey.

Medication supply in New Jersey, October 2026

As of mid-October 2026, the FDA's drug shortage database lists mixed amphetamine salts tablets, lisdexamfetamine and extended-release methylphenidate tablets as current shortages. Practical steps: call the pharmacy to confirm stock before a prescription is sent, ask about other strengths or makers of the same medication, and tell the prescriber early if a fill falls through. A newer option, centanafadine (Simtriyo), was approved by the FDA on July 24, 2026; as of October 2026, DEA scheduling was pending.

Support in New Jersey that is not the practice

• NAMI New Jersey runs a helpline, support programs and local affiliates across the state.
• New Jersey Mental Health Cares, from the Mental Health Association in New Jersey, offers help by email, a directory of services and a link to find your local emergency screening center.
• In a crisis, call or text 988, or go to your county's psychiatric emergency screening center or the nearest emergency room. Dr. Shershow's practice is not an emergency service.

For costs, the office can tell you the current fees and how insurance works with the practice. See fees and insurance.